Figure 1.
Toxicity analysis of patients with LB B-ALL who received tisagenlecleucel. (A) Overall proportions of CRS and ICANS severity (no toxicity, grade 1, grade 2, grade 3, and grade 4) among patients with LB B-ALL who received tisagenlecleucel in the entire cohort (row 1), then stratified by LB disease <5% marrow blasts (row 2) and no detectable disease (row 3). (B) Median toxicity duration of CD19–CAR-T cell recipients with LB B-ALL who experienced any grade CRS (pink) and/or ICANS (blue) with median day of onset and offset indicated in pink and blue, respectively. (C) CD19–CAR-T cell recipients with LB B-ALL who experienced any grade CRS (black line) and/or ICANS (gray line), with duration of toxicity in days. Patients who received tocilizumab (orange inverted triangle) with or without steroids (green triangle) are indicated on the day of first administration of each drug. (D) CD19–CAR-T cell recipients with LB B-ALL who experienced ≥grade 3 CRS (black line) and/or ICANS (gray line), with duration of toxicity in days. Patients who received tocilizumab (orange inverted triangle) with or without steroids (green triangle) are indicated on the day of first administration of each drug. ∗Single outlier with prolonged neurotoxicity (209 days) due to persistent facial nerve palsy, despite resolution of acute toxicity and hospital discharge at day 17 post–CAR-T. BM, bone marrow.

Toxicity analysis of patients with LB B-ALL who received tisagenlecleucel. (A) Overall proportions of CRS and ICANS severity (no toxicity, grade 1, grade 2, grade 3, and grade 4) among patients with LB B-ALL who received tisagenlecleucel in the entire cohort (row 1), then stratified by LB disease <5% marrow blasts (row 2) and no detectable disease (row 3). (B) Median toxicity duration of CD19–CAR-T cell recipients with LB B-ALL who experienced any grade CRS (pink) and/or ICANS (blue) with median day of onset and offset indicated in pink and blue, respectively. (C) CD19–CAR-T cell recipients with LB B-ALL who experienced any grade CRS (black line) and/or ICANS (gray line), with duration of toxicity in days. Patients who received tocilizumab (orange inverted triangle) with or without steroids (green triangle) are indicated on the day of first administration of each drug. (D) CD19–CAR-T cell recipients with LB B-ALL who experienced ≥grade 3 CRS (black line) and/or ICANS (gray line), with duration of toxicity in days. Patients who received tocilizumab (orange inverted triangle) with or without steroids (green triangle) are indicated on the day of first administration of each drug. ∗Single outlier with prolonged neurotoxicity (209 days) due to persistent facial nerve palsy, despite resolution of acute toxicity and hospital discharge at day 17 post–CAR-T. BM, bone marrow.

This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal